Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia

Schizophrenia Research

Volumn 71, Issue 2-3, 2004, Pages 371-375

  Yoder, Karmen K ^a   Hutchins, Gary D ^a   Morris, Evan D ^a,b   Brashear, Allison ^c   Wang, Chunzi ^a   Shekhar, Anantha ^c  

^a DIVISION OF RESEARCH   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Caudate; Dopamine transporter; PANSS; Putamen; Schizophrenia; Tardive dyskinesia

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BINDING; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; BINDING SITES; CAUDATE NUCLEUS; COGNITION DISORDERS; CORPUS STRIATUM; DEPRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; SCHIZOPHRENIA;

EID: 4944242932     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.03.015     Document Type: Article

References (18)

1. Allard P., Eriksson K., Ross S., Marcusson J. Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugs. Psychopharmacology (Berl.). 102:1990;291-294
2. Brashear A., Mulholland K.G., Zheng Q.-H., Farlow M.R., Siemers E.R., Hutchins G.D. PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism. Mov. Disord. 14:1999;132-137
3. Gunne L.M., Growdon J., Glaeser B. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology (Berl.). 77:1982;134-139
4. Hietala J., Syvalahti E., Vilkman G., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Eronen E., Ruotsalainen U., Salokangas R. Depressive symptoms and presynaptic dopamine function in neuroleptic-naïve schizophrenia. Schizophr. Res. 35:1999;41-50
5. Huang N.Y., Kostrzewa R.M. Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 271:1994;433-437
6. Huang N.Y., Kostrzewa R.M., Li C., Perry K.W., Fuller R.W. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates. J. Pharmacol. Exp. Ther. 280:1997;268-276
7. Laakso A., Vilkman H., Alakare B., Haaparanta M., Bergman J., Solin O., Peurasaari J., Rakkolainen V., Syvalahti E., Hietala J. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am. J. Psychiatry. 157:2000;269-271
8. Laakso A., Bergman J., Haaparanta M., Vilkman H., Solin O., Syvalahti E., Hietala J. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr. Res. 52:2001;115-120
9. Laruelle M., Abi-Dargham A., van Dyck C., Gil R., D'Souza D., Krystal J., Seibyl J., Baldwin R., Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]-CIT. Biol. Psychiatry. 47:2000;371-379
10. Lavalaye J., Linszen D., Booij J., Dingemans P., Reneman L., Habraken J., Gersons B., van Royen E. Dopamine transporter density in young patients with schizophrenia assessed with [123I]FP-CIT SPECT. Schizophr. Res. 47:2001;59-67
11. Lavalaye J., Sarlet A., Booij J., Linszen D., Reneman L., Gersons B., van Royen E. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology. 155:2001;107-109
12. Lindenmayer J., Bernstein-Hyman R., Grochowski S. Five-factor model of schizophrenia. J. Nerv. Ment. Dis. 182:1994;631-638
13. Lindenmayer J., Grochowski S., Hyman R. Five factor model of schizophrenia: replication across samples. Schizophr. Res. 14:1995;229-234
14. Logan J., Fowler J., Volkow N., Wang G.-J., Ding Y.-S., Alexoff D. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16:1996;834-840
15. Reader T., Ase A., Huang N., Hebert C., van Gelder N. Neuroleptics and dopamine transporters. Neurochem. Res. 23:1998;73-80
16. Scheffel U., Steinert C., Kim S., Ehlers M., Boja J., Kuhar M. Effect of dopaminergic drugs on the in vivo binding of [3H]WIN 35,428 to central dopamine transporters. Synapse. 23:1996;61-69
17. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Wallace E., Zoghbi S.S., Zea-Ponce Y., Baldwin R.M., Charney D.S., Hoffer P.B. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J. Nucl. Med. 36:1995;1175-1181
18. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley S.J., Hitzemann R., Smith G., Fields S.D., Gur R. Dopamine transporters decrease with age. J. Nucl. Med. 37:1996;554-559